Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR)

Jane Street Group LLC bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 199,006 shares of the company’s stock, valued at approximately $720,000. Jane Street Group LLC owned 0.24% of Atyr PHARMA at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Alterna Wealth Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $36,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $37,000. Raymond James Financial Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $39,000. XTX Topco Ltd acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $40,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $53,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Monday, May 19th. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Atyr PHARMA presently has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Trading Down 1.3%

NASDAQ:ATYR opened at $3.75 on Monday. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $3.24 and a two-hundred day moving average price of $3.42. The company has a market cap of $333.77 million, a P/E ratio of -3.99 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. As a group, analysts expect that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.